Results At week 24, a greater proportion of patients on ofatumumab compared with placebo achieved an ACR20 response (50% vs 27%, p<0.001) and a good or moderate EULAR response (67% vs 41%, p<0.001). All other key secondary efficacy endpoints were significantly improved on ofatumumab. Efficacy observed by 8 weeks was sustained throughout the study. The most common AE for ofatumumab versus placebo were rash (21% vs <1%) and urticaria (12% vs <1%), mostly occurring on the first infusion day. Overall, first-dose infusion reactions were 68% for ofatumumab and 6% for placebo, mostly mild to moderate; second-dose infusion reactions markedly declined (<1% and 0%). Serious AE were reported in 5% of ofatumumab versus 3% of placebo patients. Infection rates were 32% and 26% (serious infections <1% and 2%), respectively. One death (interstitial lung disease), unrelated to study drug, was reported on ofatumumab. No antidrug antibodies were detected in ofatumumab patients.

]]>https://dev.proinvestor.com/forum/topic/448370/results-at-week-24-a-greater-proportion-of-patients-on-ofatumumab-compared-with-placebo-achieved-an-acr20-response-50-vs-27-p0001-and-a-good-or-moderate-eular-response-67-vs-41-p0001-aRSS for NodeSat, 20 Jun 2026 08:32:03 GMTTue, 30 Aug 2011 12:51:07 GMT60